EQUITY.GURU podcast - Investing for millennials and madmen
Business:Investing
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.
Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!
A Closer Look: 1933 Industries (TGIF.C) focuses on fundamentals in legal cannabis market, who woulda thunk it?
A Closer Look - Rare earth metals miner, Defense Metals (DEFN.V), proving out big numbers at BC property
A Closer Look with Gaalen Engen: Azincourt Energy (AAZ.V) turning Athabasca uranium project into gold
A Closer Look with Ethan Reyes: CannaVerde Pharma positions to capitalize on Colombia's legal cannabis market
A Closer Look: 3D Sustainable Developments is building the world of tomorrow
A Closer Look with Ethan Reyes: ThinkMyco pushes the button on magic mushroom market
Equity.Guru podcast: Andrea Dobbs - a Vancouver rec weed-seller spills the beans
Equity.Guru podcast: Experion Holdings (EXP.V) and the art of executive accountability
Equity.Guru podcast: New Wave Esports maps the future of Esports
Equity.Guru podcast: CopperBank Resources (CBK.V) - a call option on copper that never expires
Equity.Guru podcast: Eureka 93 (ERKA.C) provides answers on dissolved partnerships and 15:1 share rollback
Equity.Guru podcast: Ampd Technologies' high computing solutions revolutionizing the cloud
Equity.Guru Podcast: Fake news in the age of cannabis – featuring Khiron Life Sciences (KHRN.V)
Equity.Guru podcast: Blockchain Foundry (BCFN.C) and the future of cryptocurrency
Equity.Guru podcast: 1933 Industries (TGIF.C) expands to service massive CBD health and wellness market
Equity.Guru podcast: Mag One (MDD.C) and the subtle art of giving a f*ck about the environment
Equity.Guru podcast: Blissco's blissful part in the success of Supreme Cannabis (FIRE.T)
Equity.Guru podcast: It is as it ever was - The Vancouver Island gold rush that helped build B.C.
Equity.Guru podcast: Weekly Crypto Countdown July 12, 2019
Equity.Guru podcast: ProMis Neurosciences (PMN.T) and the fight against Alzheimer's
Join Podbean Ads Marketplace and connect with engaged listeners.
Advertise Today
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Aligned Money Show
Dubai Property Podcast
IBKR Podcasts
The Ramsey Show
The Clark Howard Podcast